Memorandum

Date: April 29, 2015

To: Clinical Adult/Pediatric Hematology/Oncology Physicians and Nurses, Pediatric Nephrologists; Immunodeficiency Physicians, Rheumatologists, LIC, Mobile

From: Iwona Auer-Grzesiak, MD, FRCPC

Re: Discontinuation of Flow Cytometry Lymphocyte Subset and Rituxim Panels

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Messages:

Effective April 30, 2015, the following Flow Cytometry tests will be discontinued - Lymphocyte Subset Panel and Rituxim Panel.

Importance/Impact:

The Rituxim panel enumerates CD19 and CD20 positive B lymphocytes in peripheral blood. Currently, follow-up of patients on Rituximab therapy (including non-oncologic applications) is done clinically; therefore, Flow Cytometry testing is not required.

The Lymphocyte Subset Panel, which measures the fractions of T, B and NK cells in peripheral blood, can be replaced with our Immunodeficiency Panel (IDEF).

Background / Action Required:

Requests for Immunodeficiency Panel (IDEF) testing will be limited to Pediatric Nephrologists, Hematology/Oncology and Immunodeficiency/Allergy physicians.

Inquiries and feedback may be directed to:

Dr. Iwona Auer-Grzesiak, 403-944-8225

This memorandum has been reviewed and approved by:

Meer-Taher Shabani-Rad, MD, Clinical Section Chief, Hematology and Transfusion Medicine